A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05668741 |
Recruitment Status :
Recruiting
First Posted : December 30, 2022
Last Update Posted : May 9, 2024
|
Sponsor:
Vertex Pharmaceuticals Incorporated
Collaborator:
Moderna, Inc
Information provided by (Responsible Party):
Vertex Pharmaceuticals Incorporated
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | March 2025 |